Advent Capital Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-16,000
Closed -$4.52M 227
2025
Q3
$4.52M Buy
16,000
+1,000
+7% +$290K 0.1% 135
2025
Q2
$4.19M Buy
+15,000
New +$4.25M 0.09% 140
2025
Q1
Sell
-10,000
Closed -$2.61M 213
2024
Q4
$2.61M Buy
+10,000
New +$2.97M 0.06% 146
2024
Q2
Sell
-10,000
Closed -$2.84M 200
2024
Q1
$2.84M Buy
10,000
+5,331
+114% +$1.56M 0.07% 124
2023
Q4
$1.34M Buy
+4,669
New +$1.27M 0.03% 164
2023
Q3
Sell
-7,000
Closed -$1.55M 200
2023
Q2
$1.55M Hold
7,000
0.03% 195
2023
Q1
$1.69M Buy
+7,000
New +$1.72M 0.03% 173
2022
Q2
Sell
-15,000
Closed -$3.63M 252
2022
Q1
$3.63M Hold
15,000
0.06% 186
2021
Q4
$3.38M Buy
+15,000
New +$3.17M 0.06% 179
2018
Q4
Sell
-22
Closed -$5K 248
2018
Q3
$5K Buy
+22
New +$4.34K ﹤0.01% 272
2018
Q2
Sell
-30,798
Closed -$5.25M 280
2018
Q1
$5.25M Buy
+30,798
New +$5.65M 0.1% 162
2017
Q3
Sell
-37,500
Closed -$6.46M 293
2017
Q2
$6.46M Buy
+37,500
New +$6.1M 0.12% 143
2016
Q1
Sell
-20,000
Closed -$3.29M 441
2015
Q4
$3.29M Sell
20,000
-7,000
-26% -$1.1M 0.05% 251
2015
Q3
$3.73M Buy
+27,000
New +$4.26M 0.06% 234

Other funds holding AMGN

Advent Capital Management's AMGN Position: Q4 2025 in Review

Advent Capital Management sold out of Amgen (AMGN) in Q4 2025, closing a stake of 16,000 shares — an estimated $4.52M sold.

Advent Capital Management first reported a position in AMGN in Q3 2015 and held it in 14 quarters. The position peaked at $6.46M in Q2 2017. 3,088 funds tracked by Wall St. Rank hold AMGN as of Q4 2025.

  • Advent Capital Management reported no remaining Amgen position as of Q4 2025 after selling out during the quarter.
  • Advent Capital Management sold 16,000 Amgen shares in Q4 2025, an estimated $4.52M.
  • Advent Capital Management first reported a position in Amgen in Q3 2015 and held it in 14 quarters.
  • Advent Capital Management's Amgen position peaked at $6.46M in Q2 2017.
  • 3,088 funds tracked by Wall St. Rank held Amgen as of Q4 2025.

Based on Advent Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.